BNP Paribas Financial Markets Buys 16,663 Shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX)

BNP Paribas Financial Markets raised its stake in shares of Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) by 375.6% in the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,099 shares of the company’s stock after purchasing an additional 16,663 shares during the quarter. BNP Paribas Financial Markets’ holdings in Syndax Pharmaceuticals were worth $406,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds have also bought and sold shares of the company. SG Americas Securities LLC bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter worth approximately $637,000. Assenagon Asset Management S.A. lifted its holdings in shares of Syndax Pharmaceuticals by 54.3% in the 2nd quarter. Assenagon Asset Management S.A. now owns 428,949 shares of the company’s stock worth $8,806,000 after acquiring an additional 151,021 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in shares of Syndax Pharmaceuticals by 18.9% in the 2nd quarter. Bank of New York Mellon Corp now owns 291,826 shares of the company’s stock worth $5,991,000 after acquiring an additional 46,463 shares during the last quarter. Peregrine Capital Management LLC lifted its holdings in shares of Syndax Pharmaceuticals by 1.3% in the 2nd quarter. Peregrine Capital Management LLC now owns 198,659 shares of the company’s stock worth $4,078,000 after acquiring an additional 2,580 shares during the last quarter. Finally, nVerses Capital LLC bought a new stake in shares of Syndax Pharmaceuticals in the 2nd quarter worth approximately $33,000.

Analyst Upgrades and Downgrades

SNDX has been the subject of a number of recent research reports. Citigroup boosted their price objective on shares of Syndax Pharmaceuticals from $37.00 to $45.00 and gave the stock a “buy” rating in a report on Tuesday, November 19th. StockNews.com lowered shares of Syndax Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Saturday, November 23rd. The Goldman Sachs Group raised their price target on shares of Syndax Pharmaceuticals from $30.00 to $33.00 and gave the stock a “buy” rating in a report on Thursday, November 7th. Stifel Nicolaus raised their target price on Syndax Pharmaceuticals from $40.00 to $41.00 and gave the stock a “buy” rating in a research note on Monday, October 14th. Finally, JPMorgan Chase & Co. raised their target price on Syndax Pharmaceuticals from $33.00 to $38.00 and gave the stock an “overweight” rating in a research note on Thursday, November 21st. One investment analyst has rated the stock with a sell rating, one has assigned a hold rating and ten have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $37.64.

Syndax Pharmaceuticals Stock Performance

Syndax Pharmaceuticals stock opened at $13.93 on Friday. The stock’s 50 day simple moving average is $17.81 and its two-hundred day simple moving average is $19.46. Syndax Pharmaceuticals, Inc. has a fifty-two week low of $13.26 and a fifty-two week high of $25.34. The stock has a market cap of $1.19 billion, a price-to-earnings ratio of -3.84 and a beta of 0.86.

Syndax Pharmaceuticals (NASDAQ:SNDX) last released its earnings results on Tuesday, November 5th. The company reported ($0.98) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.13) by $0.15. The business had revenue of $12.50 million for the quarter, compared to analysts’ expectations of $9.16 million. During the same quarter in the previous year, the business posted ($0.73) earnings per share. On average, analysts predict that Syndax Pharmaceuticals, Inc. will post -2.39 earnings per share for the current year.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are revumenib, a potent, selective, small molecule inhibitor of the menin-MLL binding interaction for the treatment of KMT2A rearranged, acute leukemias, and solid tumor; and SNDX-6352 or axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1, or CSF-1 receptor for the treatment of patients with chronic graft versus host disease (cGVHD) and idiopathic pulmonary fibrosis (IPF).